Capecitabine (Cp) and Somatostatine Analog (SSA) Suitable Treatment for Progressing G1-G2 Neuroendocrine Tumors (WD NET) Abstract #888

Introduction: Results from phase II and non-randomized trials with metronomic 5-FU in combination with SSA in well-differentiated (WD) NET are limited, and considered investigational.
Aim(s): We evaluate our experience in metastatic WD NET patients (pts) treated with Cp and SSA metronomic regimen.
Materials and methods: From October 2005 to December 2013, 30 WD NET pts with progressive disease after failure of SSA and/or CT, Everolimus, PRRT were treated with Cp and SSA. The primary tumor site was pancreas (P) in 12 pts, gastrointestinal tract (GI) in eight pts, lung (L) in five pts, and unknown (U) in five pts. Pts received Cp 1000 mg/mq/bidie os days 1-14 and SSA (octreotide LAR 30 mg 1 fl im q28 or lanreotide LAR 120 mg 1 fl im q28). Treatment efficacy was evaluated by response rate according to RECIST criteria and in terms of PFS. Safety and tolerability were evaluated by assessing the onset of adverse events and treatment feasibility.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Riccardo Marconcini
Keywords: capecitabine

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1110 Chemotherapy with Capecitabine plus Temozolomide (CAP-TEM) in Patients with Advanced Neuroendocrine Neoplasms (NENs): An Italian Multicenter Retrospective Analysis
Introduction: A combination of capecitabine (CAP) and temozolomide (TEM) has been successfully used as first-line treatment in pancreatic neuroendocrine neoplasms (pNENs).
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Francesca Spada
Keywords: NEN, NET, chemotherapy
#1120 Retrospective Comparison of Chemotherapy Treatment with Capecitabine Alone or Fluropirimidine Plus Oxaliplatin in Advanced and Pretreated NET
Introduction: Oxaliplatine plus fluoropirimidine and capecitabine treatment alone are considered investigational treatments in well-differentiated (WD) NET
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Riccardo Marconcini
#891 Metastatic G1-G2 Neuroendocrine Tumors (WDNET) Treated with Sequences of Different Somatostatine Analogs (SSA) - Lanreotide LAR (La), Octreotide LAR (Oc): A Single Center Experience
Introduction: PROMID and CLARINET trials demonstrate an improvement in PFS of SSA v. placebo in WDNET.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. Riccardo Marconcini
#892 Sunitinib in Gastroeneteropancreatic Neuroendocrine Tumor (GEP-NET) after Failure of Previous Treatments, Including Everolimus: A Series of Five Clinical Cases
Introduction: In a recent phase III study, Sunitinib has shown significant improvement of progression-free survival in patients with pancreatic NET.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Riccardo Marconcini
Keywords: sunitinib, everolimus
#3022 Diagnostic Accuracy of 68Gallium Positron Emission Tomography (68Ga PET), Endoscopic Ultrasound (EUS) and Computed Tomography in the Assessment of Lymphnode Metastases by Nonfunctioning Pancreatic Neuroendocrine Neoplasms
Introduction: The presence of nodal metastasis is one of the most important predictive factors for recurrence after radical surgery for nonfunctioning Pancreatic Neuroendocrine Neoplasms (NF-PanNEN). Nevertheless, it is not clear which is the best diagnostic examination to identify preoperatively lymphnodal metastasis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr. Fabio Giannone